Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gemfibrozil
Drug ID BADD_D01012
Description Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Indications and Usage Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Marketing Status approved
ATC Code C10AB04
DrugBank ID DB01241
KEGG ID D00334
MeSH ID D015248
PubChem ID 3463
TTD Drug ID D05VIX
NDC Product Code 15440-1025; 51655-143; 57237-163; 65862-624; 71205-169; 71335-0899; 75834-131; 62991-2883; 65862-424; 50090-5808; 53002-2068; 55700-493; 68071-4053; 71610-601; 0615-8354; 43063-921; 50268-350; 68788-7964; 70934-255; 71335-0971; 61919-967; 68071-2296; 71610-107; 65691-0089; 24658-260; 43602-452; 71335-0051; 16714-101; 70518-1563; 71335-2025; 49452-3263; 16571-784; 63187-146; 63187-772; 70771-1431; 71335-0515; 76282-225; 0071-0737; 60687-224; 68382-553; 71209-008; 71335-1902; 72578-066; 71335-1996; 71610-200; 66651-905; 31722-128; 42806-260; 69097-821; 72865-186; 43063-745; 53002-1068
UNII Q8X02027X3
Synonyms Gemfibrozil | Gemfibrosil | Ausgem | Bolutol | Chem mart Gemfibrozil | CI-719 | CI 719 | CI719 | DBL Gemfibrozil | Decrelip | Gemfi 1A Pharma | Gemfibrozilo Bayvit | Bayvit, Gemfibrozilo | Gemfibrozilo Bexal | Gemfibrozilo Ur | Gemhexal | Gen-Gemfibrozil | Gen Gemfibrozil | GenGemfibrozil | GenRX Gemfibrozil | Gemfibrozil, GenRX | Healthsense Gemfibrozil | Gemfibrozil, Healthsense | Jezil | Lipazil | Lipox Gemfi | Litarek | Lopid | Lipur | Lopid R | Novo-Gemfibrozil | Novo Gemfibrozil | Nu-Gemfibrozil | Nu Gemfibrozil | NuGemfibrozil | Pilder | PMS-Gemfibrozil | PMS Gemfibrozil | SBPA Gemfibrozil | Gemfibrozil, SBPA | Terry White Chemists Gemfibrozil | Trialmin | Apo-Gemfibrozil | Apo Gemfibrozil | ApoGemfibrozil
Chemical Information
Molecular Formula C15H22O3
CAS Registry Number 25812-30-0
SMILES CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis22.07.03.006; 11.01.13.004--
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.0010.000107%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.0150.000107%
Synovitis15.04.02.001--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urogenital disorder21.10.05.010; 20.08.01.002--Not Available
Urticaria23.04.02.001; 10.01.06.0010.000966%
Vasculitis10.02.02.006; 24.12.04.027--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.000236%
Vomiting07.01.07.0030.000783%
Weight decreased13.15.01.005--
Balance disorder08.01.03.081; 17.02.02.0070.000107%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.003--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.04.036--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Antinuclear antibody positive13.06.01.003--Not Available
Bacterial infection11.02.01.005--Not Available
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Mediastinal disorder22.09.03.001--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages